摘要
目的探讨以降低甘油三酯为主的血脂调整药对高脂血症脂肪肝的防治作用。方法观察Ｂｅｚａｆｉｂｒａｔｅ对高脂饮食诱发Ｗｉｓｔａｒ大鼠高脂血症和脂肪肝形成的影响（治疗组，ｎ＝８），并设模型组和正常饮食组作对照。结果与正常组相比，模型组血脂和肝匀浆脂肪含量均显著升高，肝组织学呈中至重度脂肪变。与模型组相比，治疗组血清甘油三酯和总胆固醇显著下降，但血清转氨酶和肝匀浆脂质含量却呈升高趋势，肝脏病理学变化与模型组基本相近。结论Ｂｅｚａｆｉｂｒａｔｅ虽可显著降低高脂饮食诱发的高脂血症，但对肝内脂肪沉积并无防治作用。
Aim To explore
the effect of serum lipid adjustment drugs with decreasing serum triglyceride mainly on the
development of hyperlipidemia and fatty liver. Methods We observed the effect of Bezafibrate
on the development of hyperlipidemia and fatty liver in Wistar rats chronically fed with high fat
diet(the therapeutic group,n=8),and the model group and normal diet group as control. Results
The content of triglyceride and total cholesterol both in serum and liver in the model group were
significantly higher than those in normal group,furtheremore,moderate and severe hepatic
steatosis in model group were observed.The level of serum triglyceride and total cholesterol in
the therapeutic group were significantly lower than those in model group;But both serum
aminotransferase activity and the content of hepatic triglyceride in the therapeutic group were
slightly higher than those in the model group,moreover,the difference of changes of hepatic
pathology between two groups were obviousless. Conclusions Although Bezafibrate may
decrease obviously the serum lipid induced by high fat diet,it has no effect on the prevention
and treatment of fatty liver.
出处
《胃肠病学和肝病学杂志》
CAS
1999年第2期100-102,共3页
Chinese Journal of Gastroenterology and Hepatology
